Loxitane, Adasuve(loxapine)
Adasuve, Loxapine, Loxitane (loxapine) is a small molecule pharmaceutical. Loxapine was first approved as Loxitane im on 1982-01-01. It is used to treat psychotic disorders and schizophrenia in the USA. It has been approved in Europe to treat bipolar disorder and schizophrenia. The pharmaceutical is active against D(3) dopamine receptor, D(4) dopamine receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2C. In addition, it is known to target histamine H1 receptor, 5-hydroxytryptamine receptor 6, potassium channel subfamily T member 1, and 5-hydroxytryptamine receptor 7.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Adasuve, Loxapine (discontinued: Loxapine, Loxitane, Loxitane c, Loxitane im)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Loxapine succinate
Loxapine hydrochloride
Loxapine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ADASUVE | Alexza Pharmaceuticals | N-022549 RX | 2012-12-21 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| loxapine | ANDA | 2025-10-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| schizophrenia | EFO_0000692 | D012559 | F20 |
| psychotic disorders | — | D011618 | F20.81 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J2062 | Loxapine for inhalation, 1 mg |
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | 2 | — | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | 1 | — | 1 | 4 |
| Psychomotor agitation | D011595 | — | — | — | 1 | 1 | — | 1 | 3 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | 2 | — | — | — | 3 |
| Headache | D006261 | — | R51 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiotoxicity | D066126 | EFO_1001482 | — | 1 | — | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | 1 | — | — | — | — | 1 |
| Obstructive lung diseases | D008173 | — | — | 1 | — | — | — | — | 1 |
| Cigarette smoking | D000073865 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Loxapine |
| INN | loxapine |
| Description | Loxapine is a dibenzooxazepine. It has a role as an antipsychotic agent and a dopaminergic antagonist. |
| Classification | Small molecule |
| Drug class | tricyclic compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1977-10-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL831 |
| ChEBI ID | 50841 |
| PubChem CID | 3964 |
| DrugBank | DB00408 |
| UNII ID | LER583670J (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNT1
KCNT1
Organism
Homo sapiens
Gene name
KCNT1
Gene synonyms
KIAA1422
NCBI Gene ID
Protein name
potassium channel subfamily T member 1
Protein synonyms
KCa4.1, potassium channel, sodium activated subfamily T, member 1, potassium channel, subfamily T, member 1, Sequence like a calcium-activated K+ channel
Uniprot ID
Mouse ortholog
Kcnt1 (227632)
potassium channel subfamily T member 1 (Q8C3E7)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Loxapine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,447 documents
View more details
Safety
Black-box Warning
Black-box warning for: Loxapine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,128 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use